Enterprise Value

743.4M

Cash

377.6M

Avg Qtr Burn

-16.89M

Short % of Float

4.13%

Insider Ownership

14.08%

Institutional Own.

63.71%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Bitopertin (GlyT1 inhibitor) Details
erythropoietic porphyrias, X-linked protoporphyria

Phase 2

Data readout

Bitopertin (GlyT1 inhibitor) Details
Rare genetic disease, Anemia

Phase 1/2

Data readout

DISC-0974 Details
Myelofibrosis, Kidney disease, Anemia

Phase 1/2

Data readout

Phase 1

Initiation

GEM103 Details
Age-related macular degeneration

Failed

Discontinued

GEM103 Details
Wet age-related macular degeneration , Age-related macular degeneration

Failed

Discontinued